innovations. As an honoree, Nicole will be celebrated at a dinner at The Edison Ballroom in New York City on February 11, 2025. For more information about MM+M's 40 Under 40 program, visit www.mmm40under40.com. About Petauri: Petauri is a...
that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November 2024, this designation marks a crucial...
diabetic indications. The newly completed study builds upon a previous DIO study in which BLX-7006 demonstrated a promising 15.6 % weight loss. In the expanded study, BLX-7006 achieved a substantial 29% weight loss, attributed to evaluating higher...
nearly 20 years of medical device experience, including serving as the chief operating officer of Axonics for more than 10 years where he played a critical role in implementing lean operations and compliant quality systems that helped to pave the...
with poor vision in dim light and night blindness. Ultimately, patients lose all of their sight by middle age. But since 2018, Dr. Nagiel and his team at the Vision Center of Children’s Hospital Los Angeles have been treating these patients with a...
Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1. Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates (protofibrils2), as well as insoluble Aβ aggregates...
in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). This is the...
company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary data from the accelerated Phase 1a trial in patients with...
decline through this mechanism. It is estimated there were approximately 900,000 dementia patients in South Korea in 2021,1 with one in ten people over the age of 65 suffering from dementia,1 and one in five from mild cognitive impairment (MCI).2...
(SAB). In this capacity, Dr Sadeh will play a significant role in advancing the clinical development of Scinai's lead IL-17 program along with other promising assets in their unique VHH antibody pipeline. Dr. Sadeh is an accomplished...
(Duchenne), a rare muscle-wasting neurological disorder. Prior to joining NS Pharma, Foy served in leadership roles for 17 years in the pharmaceutical industry, with more than 24 years of experience both in sales and in cross-functional positions...
technology pioneer Neoplas Med GmbH is intensifying its strategic collaboration with Niterra Ventures Company, via an $18M capital increase to expand the market further for innovative wound care technology products. With a total investment of $25M....
an artificial intelligence (AI) solution company for brain disease, announced on the "Neurophet AQUA", has obtained 510(k) clearance from U.S. Food and Drug Administration (FDA) for its newly integrated multiple sclerosis (MS) analysis...
The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...
truncated, often nonfunctional protein and effectively causing a loss of function. Their study appeared online on November 01, 2024 in the journal Experimental & Molecular Medicine. Highlighting the significance of this achievement, senior author...
Bola Jibodu, a Sickle Cell Warrior from the UK. Especially after a major SCD drug was recently withdrawn from the market,[1] patients will be looking for other options to prevent pain and other dangerous complications from a disease that robs them...
neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal NUZ-001's unique mechanism of action in preventing the aggregation of TAR DNA-binding...
manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment....
regulatory demands, and the patent cliff challenge. The McKinsey Global Institute estimates that gen AI could generate $18 billion to $30 billion of economic value in commercial functions at Pharmaceutical and MedTech companies. The Agentic AI...
(exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older with (1) sickle cell disease (SCD) with recurrent vaso-occlusive crises or (2) transfusion-dependent...
